We also demonstrate that PLA2G16 overexpression reduced sensitivity to chemotherapeutic drugs in both a dose and time-dependent manner, suggesting the development of small molecular inhibitors against PLA2G16 could be used to increase the sensitivity of osteosarcoma standard chemotherapy. The gene discussed is PLAAT3; the disease is osteosarcoma.